Celldex Therapeutics Overview
Celldex Therapeutics Target Price
Where could CLDX trade next? Consensus target price: $58.
Get informed when a big investor buys or sells
+ FollowShare Price
$44.87
Average Target Price
$58.00
29.3% upside
29.3% upside12 analysts in the last 4 months
High: $100 | Low: $40
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-07 | Barclays | $53 | 18.1% upside |  |
| 2026-07-29 | Wells Fargo | $72 | 60.5% upside | |
| 2026-07-22 | Cantor Fitzgerald | $61 | 35.9% upside | |
| 2026-07-22 | Wells Fargo | $48 | 7% upside | |
| 2026-07-22 | Morgan Stanley | $40 |  10.9% downside | |
| 2026-07-22 | Canaccord Genuity | $60 | 33.7% upside | |
| 2026-07-22 | Leerink Partners | $70 | 56% upside | |
| 2026-07-20 | GuggenheimYatin Suneja | $100 | 122.9% upside | |
| 2026-06-10 | UBS | $45 | 0.3% upside | |
| 2026-05-13 | Wells FargoDerek Archila | $54 | 20.3% upside | |
| 2026-05-08 | Barclays | $48 | 7% upside | |
| 2026-04-20 | Barclays | $45 | 0.3% upside | |
| 2025-12-17 | Barclays | $24 | 46.5% downside | |
| 2025-11-11 | Barclays | $21 | 53.2% downside | |
| 2025-10-13 | Barclays | $25 | 44.3% downside | |
| 2025-03-20 | Morgan Stanley | $46 | 2.5% upside | |
| 2024-10-29 | H.C. WainwrightJoseph Pantginis | $80 | 78.3% upside | |
| 2024-09-25 | Wells FargoDerek Archila | $44 | 1.9% downside | |
| 2024-06-17 | Stifel NicolausAlex Thompson | $58 | 29.3% upside | |
| 2023-11-10 | Wells FargoDerek Archila | $27 | 39.8% downside | |
| 2022-11-11 | Guggenheim | $63 | 40.4% upside | |